[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406332-105":59,"doc-detail-406332-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","additional-considerations-on-vonoprazan-triple-therapy-for-helicobacter-pylori-eradication-implementation-challenges-and-clinical-perspectives","Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives","","The vonoprazan (VPZ) triple therapy regimen for Helicobacter pylori (H. pylori) eradication described in prior multicenter research is supported by a scientifically structured clinical trial approach. The randomized controlled design aims to standardize treatment, simplify regimens, shorten therapy duration, and improve eradication outcomes while translating evidence into practice. Effective implementation depends on drug accessibility, multidimensional safety evaluation systems, and improved cost-effectiveness. Regional adaptability and comprehensive safety assessment are emphasized for China’s diverse healthcare environment, with further validation needed for nationwide applicability and universal use.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/additional-considerations-on-vonoprazan-triple-therapy-for-helicobacter-pylori-eradication-implementation-challenges-and-clinical-perspectives/406332/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/additional-considerations-on-vonoprazan-triple-therapy-for-helicobacter-pylori-eradication-implementation-challenges-and-clinical-perspectives/406332.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of the letter’s discussion on VPZ triple therapy implementation?","Question",{"text":113,"@type":114},"It focuses on practical implementation challenges and clinical perspectives for vonoprazan triple therapy, including how to translate efficacy results into real-world use.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which factors are highlighted as key barriers to nationwide implementation in China?",{"text":118,"@type":114},"Limited drug accessibility in primary healthcare settings, higher costs versus traditional therapies, and significant regional variation in antibiotic resistance patterns are emphasized.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are regional adaptability studies and safety assessments important?",{"text":122,"@type":114},"They help confirm VPZ regimen effectiveness and tolerability across China’s diverse populations and healthcare contexts, supporting safe and effective broader adoption.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},406332,1790813118,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":52,"preview_page_count":4},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2025 December 14; 31(46): 113528  \nDOI: 10.3748/wjg.v31.i46.113528 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nLETTER TO THE EDITOR  \nAdditional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives  \nChu-Ying Sun, Ming-Xian Chen  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nUnsolicited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B  \nNovelty: Grade B, Grade C  \nCreativity or Innovation: Grade B, Grade C  \nScientific Significance: Grade B, Grade B  \nP-Reviewer: Huang JM, Assistant Professor, China; Liu H, PhD,  \nProfessor, China  \nReceived: August 27, 2025  \nRevised: October 2, 2025  \nAccepted: November 4, 2025  \nPublished online: December 14, 2025  \nProcessing time: 104 Days and 16.8 Hours  \nChu-Ying Sun, Integrative Medicine Clinical College of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou 310012, Zhejiang Province, China  \nMing-Xian Chen, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China  \nCorresponding author: Ming-Xian Chen, MD, Professor, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Hangzhou 310012, Zhejiang Province, [China.](China. chenmingxian2005@126.com)[ chenmingxian2005@126.com](China. chenmingxian2005@126.com)  \nAbstract  \nThe vonoprazan (VPZ) triple therapy regimen for Helicobacter pylori (H. pylori) eradication developed by Han et al employs a scientifically rigorous clinical trial design. This multicenter randomized controlled trial establishes a standardized treatment framework aimed at improving H. pylori eradication rates, focusing on simplifying treatment regimens, shortening therapy duration, and optimizing therapeutic outcomes. The core of clinical translation lies in improving drug accessibility, establishing multidimensional safety evaluation systems, and optimizing cost-effectiveness. Conducting regional adaptability studies and comprehensive safety assessments is crucial for enhancing VPZ regimen effectiveness in China’s diverse healthcare environments. This study provides important evidence-based support for optimizing H. pylori treatment strategies in China, though further validation of universal applicability for nationwide implementation remains necessary.  \nKey Words: Helicobacter pylori ; Vonoprazan; Multicenter trial; Regional differences; Clinical implementation  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 14, 2025  Volume 31  Issue 46   \nSun CY et al. VPZ triple therapy for Helicobacter pylori  \nCore Tip: Han et al’s multicenter trial demonstrates vonoprazan triple therapy’s superior efficacy over standard bismuth quadruple therapy for Helicobacter pylori eradication in China, successful nationwide implementation faces critical challenges. Key barriers include limited drug accessibility in primary healthcare settings, higher costs compared to traditional therapies, and significant regional variations in antibiotic resistance patterns across China’s diverse population. The study’s single-province design cannot fully represent national applicability. Addressing these implementation gaps through comprehensive health system research, cost-effectiveness analyses, and multi-regional validation studies is essential for translating these promising clinical findings into improved patient outcomes across China’s heterogeneous healthcare landscape.  \nCitation: Sun CY, Chen MX. Additional considerations on vonoprazan triple therapy for Helicobacter pylori er","cbCaiqZp0fkdwNZ2","https://ap.wps.com/l/cbCaiqZp0fkdwNZ2","pdf",360056,"English","# Abstract\n# Key Words\n# Core Tip\n# Citation\n# Background and Rationale\n## H. pylori burden and current recommendations\n## Han et al trial design and treatment arms","[{\"question\":\"What is the main focus of the letter’s discussion on VPZ triple therapy implementation?\",\"answer\":\"It focuses on practical implementation challenges and clinical perspectives for vonoprazan triple therapy, including how to translate efficacy results into real-world use.\"},{\"question\":\"Which factors are highlighted as key barriers to nationwide implementation in China?\",\"answer\":\"Limited drug accessibility in primary healthcare settings, higher costs versus traditional therapies, and significant regional variation in antibiotic resistance patterns are emphasized.\"},{\"question\":\"Why are regional adaptability studies and safety assessments important?\",\"answer\":\"They help confirm VPZ regimen effectiveness and tolerability across China’s diverse populations and healthcare contexts, supporting safe and effective broader adoption.\"}]","Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives | PDF",1790564902]